Perhaps, pembrolizumab following SBRT may represent a less toxic alternative to chemoimmunotherapy when aiming to enhance response rates in M-NSCLC patients with a low PD-L1 tumor proportion score. The gene discussed is CD274; the disease is non-small cell lung carcinoma.